SWS Partners Purchases Shares of 74,582 Guardant Health, Inc. $GH

SWS Partners acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 74,582 shares of the company’s stock, valued at approximately $11,190,000. Guardant Health accounts for 2.4% of SWS Partners’ holdings, making the stock its 9th biggest holding.

A number of other large investors have also recently made changes to their positions in GH. Handelsbanken Fonder AB lifted its stake in Guardant Health by 159.9% in the second quarter. Handelsbanken Fonder AB now owns 301,041 shares of the company’s stock worth $45,165,000 after acquiring an additional 185,200 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $213,000. Allied Private Wealth LLC purchased a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $72,000. MRA Advisory Group raised its holdings in shares of Guardant Health by 6.2% in the 2nd quarter. MRA Advisory Group now owns 12,026 shares of the company’s stock valued at $1,804,000 after purchasing an additional 706 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Guardant Health by 14.5% in the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after purchasing an additional 122 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the sale, the chief executive officer owned 1,886,504 shares in the company, valued at approximately $207,307,924.56. The trade was a 10.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Terilyn J. Monroe sold 46,300 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total value of $7,645,056.00. Following the completion of the sale, the insider directly owned 22,979 shares of the company’s stock, valued at $3,794,292.48. The trade was a 66.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 784,350 shares of company stock valued at $106,504,483 over the last 90 days. 5.60% of the stock is owned by insiders.

Guardant Health Stock Performance

Guardant Health stock opened at $157.21 on Friday. Guardant Health, Inc. has a fifty-two week low of $53.40 and a fifty-two week high of $176.58. The company has a market capitalization of $21.10 billion, a P/E ratio of -45.05 and a beta of 1.60. The stock has a 50-day simple moving average of $150.40 and a 200-day simple moving average of $116.87.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on GH shares. Piper Sandler boosted their target price on shares of Guardant Health from $135.00 to $193.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. UBS Group set a $150.00 price objective on Guardant Health in a report on Wednesday, June 24th. Morgan Stanley raised their target price on Guardant Health from $175.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, Stifel Nicolaus boosted their target price on Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $183.78.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.